PT  - JOURNAL ARTICLE
AU  - Chen, Siyuan
AU  - Tan, Amelia LM
AU  - Perry, Cassandra
AU  - Churchill, Susanne
AU  - Vella, Margaret
AU  - Mao, Jenny
AU  - Viswanadham, Vinay
AU  - Kobren, Shilpa
AU  - Kohane, Isaac S
TI  - Polygenic risk scores for autoimmune related diseases are significantly different and skewed in cancer exceptional responders
AID  - 10.1101/2023.02.22.23285773
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.22.23285773
4099  - http://medrxiv.org/content/early/2023/03/06/2023.02.22.23285773.short
4100  - http://medrxiv.org/content/early/2023/03/06/2023.02.22.23285773.full
AB  - A group of 54 exceptional responders (ERs) to cancer treatment across a variety of cancers and treatments were compared to typical cancer patients using previously defined polygenic risk scores (PRS) for multiple autoimmune-related diseases including type 1 diabetes (T1D), hypothyroidism, psoriasis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel (IBD) disease. Most of the ERs were not treated with checkpoint inhibitors and included a broad array of tumor types. Significantly elevated PRSs were found between ERs relative to typical cancer patients in T1D, hypothyroidism, and psoriasis. IBD PRS scores were significantly decreased in the ERs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by 1. The People-Powered Medicine platform was made possible by a grant from the National Institutes of Health Big Data to Knowledge program (Grant #U54H6007963). 2. Moskovitz Fund for Precision Medicine 3. Millenium PharmaceuticalsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of Harvard Faculty of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll SNP data and diagnoses produced in the present study are available upon request to the authors.